{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,12]],"date-time":"2026-10-12T16:51:29Z","timestamp":1791823889536,"version":"4.3.4"},"reference-count":49,"publisher":"Springer Science and Business Media LLC","issue":"4","license":[{"start":{"date-parts":[[2020,11,2]],"date-time":"2020-11-02T00:00:00Z","timestamp":1604275200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2020,11,2]],"date-time":"2020-11-02T00:00:00Z","timestamp":1604275200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/501100000866","name":"Cardiff University","doi-asserted-by":"crossref","id":[{"id":"10.13039\/501100000866","id-type":"DOI","asserted-by":"crossref"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["J Neurol"],"published-print":{"date-parts":[[2021,4]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:p>Chimeric antigen receptor (CAR)-expressing T cells now offer an effective treatment option for people with previously refractory B cell malignancies and are under development for a wide range of other tumours. However, neurological toxicity is a common complication of CAR-T cell therapy, seen in over 50% of recipients in some cohorts. Since 2018, the term immune effector cell-associated neurotoxicity syndrome (ICANS) has been used to describe and grade neurotoxicity seen after CAR-T cells and other similar therapies. ICANS following CAR-T therapy is usually self-limiting but can necessitate admission to the intensive care unit and is rarely fatal. As CAR-T therapies enter routine clinical practice, it is important for neurologists to be aware of the nature of neurological complications. Here, we summarise the clinical manifestations, mechanisms, investigations and recommended treatment of CAR-T-related neurotoxicity, focusing on the licensed CD19 products.<\/jats:p>","DOI":"10.1007\/s00415-020-10237-3","type":"journal-article","created":{"date-parts":[[2020,11,2]],"date-time":"2020-11-02T12:03:14Z","timestamp":1604318594000},"page":"1544-1554","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":87,"title":["Neurological updates: neurological complications of CAR-T therapy"],"prefix":"10.1007","volume":"268","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-3760-6634","authenticated-orcid":false,"given":"Emma C.","family":"Tallantyre","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nia A.","family":"Evans","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jack","family":"Parry-Jones","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Matt P. G.","family":"Morgan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ceri H.","family":"Jones","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wendy","family":"Ingram","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2020,11,2]]},"reference":[{"key":"10237_CR1","doi-asserted-by":"publisher","first-page":"31","DOI":"10.1016\/S1470-2045(18)30864-7.Long-term","volume":"20","author":"FL Locke","year":"2019","unstructured":"Locke FL, Jacobson CA, Miklos DB et al (2019) Long-term safety and activity of axicabtagene ciloleucel in refractory large B cell lymphoma (ZUMA-1): a single-arm, multicentre, phase 1\u20132 trial. Lancet Oncol 20:31\u201342. https:\/\/doi.org\/10.1016\/S1470-2045(18)30864-7.Long-term","journal-title":"Lancet Oncol"},{"key":"10237_CR2","doi-asserted-by":"publisher","first-page":"2531","DOI":"10.1056\/NEJMoa1707447","volume":"377","author":"S Neelapu","year":"2017","unstructured":"Neelapu S, Locke F, Bartlett N et al (2017) Axicabtagene ciloleucel CAR T cell therapy in refractory large B cell lymphoma. N Engl J Med 377:2531\u20132544. https:\/\/doi.org\/10.1056\/NEJMoa1707447","journal-title":"N Engl J Med"},{"key":"10237_CR3","doi-asserted-by":"publisher","first-page":"S24","DOI":"10.1002\/ajh.25442","volume":"94","author":"NV Frey","year":"2019","unstructured":"Frey NV (2019) Chimeric antigen receptor T cells for acute lymphoblastic leukemia. Am J Hematol 94:S24\u2013S27. https:\/\/doi.org\/10.1002\/ajh.25442","journal-title":"Am J Hematol"},{"key":"10237_CR4","doi-asserted-by":"publisher","first-page":"849","DOI":"10.3389\/fonc.2020.00849","volume":"10","author":"C Vitale","year":"2020","unstructured":"Vitale C, Strati P (2020) CAR T cell therapy for B cell non-hodgkin lymphoma and chronic lymphocytic leukemia: clinical trials and real-world experiences. Front Oncol 10:849. https:\/\/doi.org\/10.3389\/fonc.2020.00849","journal-title":"Front Oncol"},{"key":"10237_CR5","doi-asserted-by":"publisher","first-page":"625","DOI":"10.1016\/j.bbmt.2018.12.758","volume":"25","author":"DW Lee","year":"2019","unstructured":"Lee DW, Santomasso BD, Locke FL et al (2019) Biology of blood and marrow transplantation ASTCT consensus grading for cytokine release syndrome and neurologic toxicity associated with immune effector cells. Biol Blood Marrow Transplant 25:625\u2013638. https:\/\/doi.org\/10.1016\/j.bbmt.2018.12.758","journal-title":"Biol Blood Marrow Transplant"},{"key":"10237_CR6","doi-asserted-by":"publisher","first-page":"5629","DOI":"10.1182\/blood-2019-132273","volume":"134","author":"EF Moreno Cortes","year":"2019","unstructured":"Moreno Cortes EF, Stein CK, Lengerke Diaz PA et al (2019) Chimeric antigen receptor T cell therapy pipeline at a glance: a retrospective and systematic analysis from clinicaltrials. Gov Blood 134:5629","journal-title":"Gov Blood"},{"key":"10237_CR7","doi-asserted-by":"publisher","first-page":"45","DOI":"10.1016\/j.blre.2018.11.002.Recent","volume":"34","author":"JN Brudno","year":"2019","unstructured":"Brudno JN, Kochenderfer JN (2019) Recent advances in CAR T-cell toxicity: mechanisms, manifestations and management. Blood Rev 34:45\u201355. https:\/\/doi.org\/10.1016\/j.blre.2018.11.002.Recent","journal-title":"Blood Rev"},{"key":"10237_CR8","doi-asserted-by":"publisher","first-page":"1334","DOI":"10.1093\/brain\/awz053","volume":"142","author":"DB Rubin","year":"2019","unstructured":"Rubin DB, Danish HH, Ali AB et al (2019) Neurological toxicities associated with chimeric antigen receptor T cell therapy. Brain 142:1334\u20131348. https:\/\/doi.org\/10.1093\/brain\/awz053","journal-title":"Brain"},{"key":"10237_CR9","doi-asserted-by":"publisher","first-page":"3321","DOI":"10.1182\/blood-2016-04-703751.CAR","volume":"127","author":"JN Brudno","year":"2016","unstructured":"Brudno JN, Kochenderfer JN (2016) Toxicities of chimeric antigen receptor T cells: recognition and management. Adv Cell-Based Immune TherHematol 127:3321\u20133330. https:\/\/doi.org\/10.1182\/blood-2016-04-703751.CAR","journal-title":"Adv Cell-Based Immune TherHematol"},{"key":"10237_CR10","doi-asserted-by":"publisher","first-page":"1091","DOI":"10.1007\/s40263-018-0582-9","volume":"32","author":"J Gust","year":"2018","unstructured":"Gust J, Taraseviciute A, Turtle CJ (2018) Neurotoxicity associated with CD19\u2014targeted CAR\u2014T cell therapies. CNS Drugs 32:1091\u20131101. https:\/\/doi.org\/10.1007\/s40263-018-0582-9","journal-title":"CNS Drugs"},{"key":"10237_CR11","doi-asserted-by":"publisher","first-page":"1404","DOI":"10.1158\/2159-8290.CD-17-0698.Endothelial","volume":"7","author":"J Gust","year":"2017","unstructured":"Gust J, Hay KA, Li D et al (2017) Endothelial activation and blood-brain barrier disruption in neurotoxicity after adoptive immunotherapy with CD19 CAR-T cells. Cancer Discov 7:1404\u20131419. https:\/\/doi.org\/10.1158\/2159-8290.CD-17-0698.Endothelial","journal-title":"Cancer Discov"},{"key":"10237_CR12","doi-asserted-by":"publisher","first-page":"47","DOI":"10.1038\/nrclinonc.2017.148.Chimeric","volume":"15","author":"SS Neelapu","year":"2018","unstructured":"Neelapu SS, Tummala S, Kebriael P et al (2018) Chimeric antigen receptor T cell therapy\u2014assessment and management of toxicities. Nat Rev Clin Oncol 15:47\u201362. https:\/\/doi.org\/10.1038\/nrclinonc.2017.148.Chimeric","journal-title":"Nat Rev Clin Oncol"},{"key":"10237_CR13","doi-asserted-by":"publisher","first-page":"958","DOI":"10.1158\/2159-8290.CD-17-1319","volume":"8","author":"BD Santomasso","year":"2018","unstructured":"Santomasso BD, Park JH, Salloum D et al (2018) Clinical and biological correlates of neurotoxicity associated with CAR T cell therapy in patients with B cell acute lymphoblastic leukemia. Cancer Discov 8:958\u2013971. https:\/\/doi.org\/10.1158\/2159-8290.CD-17-1319","journal-title":"Cancer Discov"},{"key":"10237_CR14","doi-asserted-by":"publisher","first-page":"42","DOI":"10.1002\/ana.25502","volume":"86","author":"J Gust","year":"2019","unstructured":"Gust J, Finney OC, Li D et al (2019) Glial injury in neurotoxicity after pediatricCD19-directed chimeric antigen receptor T cell therapy. Ann Neurol 86:42\u201354. https:\/\/doi.org\/10.1002\/ana.25502","journal-title":"Ann Neurol"},{"key":"10237_CR15","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1634\/theoncologist.2019-0646","volume":"25","author":"I Papadouli","year":"2020","unstructured":"Papadouli I, Mueller-Berghaus J, Beuneu C et al (2020) EMA review of axicabtagene ciloleucel (Yescarta ) for the treatment of diffuse large B cell lymphoma. Oncologist 25:1\u20139. https:\/\/doi.org\/10.1634\/theoncologist.2019-0646","journal-title":"Oncologist"},{"key":"10237_CR16","doi-asserted-by":"publisher","first-page":"646","DOI":"10.1093\/jnci\/djz017","volume":"111","author":"BD Hunter","year":"2019","unstructured":"Hunter BD, Jacobson CA (2019) Commentary CAR T cell associated neurotoxicity : mechanisms, clinicopathologic correlates, and future directions. J Natl Cancer Inst 111:646\u2013654. https:\/\/doi.org\/10.1093\/jnci\/djz017","journal-title":"J Natl Cancer Inst"},{"key":"10237_CR17","doi-asserted-by":"publisher","first-page":"439","DOI":"10.1056\/NEJMoa1709866.Tisagenlecleucel","volume":"378","author":"S Maude","year":"2018","unstructured":"Maude S, Laetsch T, Buechner J et al (2018) Tisagenlecleucel in children and young adults with B cell lymphoblastic leukemia. N Engl J Med 378:439\u2013448. https:\/\/doi.org\/10.1056\/NEJMoa1709866.Tisagenlecleucel","journal-title":"N Engl J Med"},{"key":"10237_CR18","doi-asserted-by":"publisher","first-page":"2545","DOI":"10.1056\/NEJMoa1708566","volume":"377","author":"S Schuster","year":"2017","unstructured":"Schuster S, Svoboda J, Chong E et al (2017) Chimeric antigen receptor T cells in refractory B cell lymphomas. N Engl J Med 377:2545\u20132554. https:\/\/doi.org\/10.1056\/NEJMoa1708566","journal-title":"N Engl J Med"},{"key":"10237_CR19","doi-asserted-by":"publisher","DOI":"10.1038\/s41409-020-01029-4","author":"T Badar","year":"2020","unstructured":"Badar T, Johnson B, Hamadani M (2020) Delayed neurotoxicity after axicabtagene ciloleucel therapy in relapsed refractory diffuse large B-cell lymphoma. Bone Marrow Transplant. https:\/\/doi.org\/10.1038\/s41409-020-01029-4","journal-title":"Bone Marrow Transplant"},{"key":"10237_CR20","unstructured":"Common Terminology Criteria for Adverse Events. https:\/\/ctep.cancer.gov\/protocoldevelopment\/electronic_applications\/docs\/CTCAE_v5_Quick_Reference_8.5x11.pdf"},{"key":"10237_CR21","doi-asserted-by":"publisher","first-page":"3322","DOI":"10.1182\/blood-2017-02-769208","volume":"129","author":"RA Gardner","year":"2017","unstructured":"Gardner RA, Finney O, Annesley C et al (2017) Intent-to-treat leukemia remission by CD19 CAR T cells of defined formulation and dose in children and young adults. Blood 129:3322\u20133331. https:\/\/doi.org\/10.1182\/blood-2017-02-769208","journal-title":"Blood"},{"key":"10237_CR22","doi-asserted-by":"publisher","first-page":"1440","DOI":"10.1182\/bloodadvances.2019001305","volume":"4","author":"RT Maziarz","year":"2020","unstructured":"Maziarz RT, Schuster SJ, Romanov VV et al (2020) Grading of neurological toxicity in patients treated with tisagenlecleucel in the JULIET trial. Blood Adv 4:1440\u20131447. https:\/\/doi.org\/10.1182\/bloodadvances.2019001305","journal-title":"Blood Adv"},{"key":"10237_CR23","doi-asserted-by":"publisher","first-page":"960","DOI":"10.1111\/ene.12690","volume":"22","author":"A Signori","year":"2015","unstructured":"Signori A, Schiavetti I, Gallo F, Sormani M (2015) Subgroups of multiple sclerosis patients with larger treatment benefits: a meta-analysis of randomized trials. Eur J Neurol 22:960\u2013966","journal-title":"Eur J Neurol"},{"key":"10237_CR24","doi-asserted-by":"publisher","first-page":"288","DOI":"10.1080\/096382800296755","volume":"22","author":"E Hakim","year":"2000","unstructured":"Hakim E, Bakheit M, Bryant TN et al (2000) The social impact of multiple sclerosis\u2014a study of 305 patients and their relatives. DisabilRehabil 22:288\u2013293. https:\/\/doi.org\/10.1080\/096382800296755","journal-title":"DisabilRehabil"},{"key":"10237_CR25","doi-asserted-by":"publisher","first-page":"95","DOI":"10.1002\/ana.23758","volume":"73","author":"R Bermel","year":"2013","unstructured":"Bermel R, You X, Foulds P et al (2013) Predictors of long-term outcome in multiple sclerosis patients treated with interferon beta. Ann Neurol 73:95\u2013103. https:\/\/doi.org\/10.1002\/ana.23758","journal-title":"Ann Neurol"},{"key":"10237_CR26","doi-asserted-by":"publisher","first-page":"278","DOI":"10.1212\/WNL.0000000000000560","volume":"83","author":"FD Lublin","year":"2014","unstructured":"Lublin FD, Reingold SC, Cohen J et al (2014) Defining the clinical course of multiple sclerosis: the 2013 revisions. Neurology 83:278\u2013286. https:\/\/doi.org\/10.1212\/WNL.0000000000000560","journal-title":"Neurology"},{"key":"10237_CR27","doi-asserted-by":"publisher","first-page":"548","DOI":"10.1002\/ana.20224","volume":"56","author":"R Rudick","year":"2004","unstructured":"Rudick R, Lee JC, Simon J et al (2004) Defining interferon beta response status in multiple sclerosis patients. Ann Neurol 56:548\u2013555. https:\/\/doi.org\/10.1002\/ana.20224","journal-title":"Ann Neurol"},{"key":"10237_CR28","doi-asserted-by":"publisher","DOI":"10.1111\/ene.12119","author":"M Romeo","year":"2013","unstructured":"Romeo M, Martinelli-Boneschi F, Rodegher M et al (2013) Clinical and MRI predictors of response to interferon-beta and glatiramer acetate in relapsing-remitting multiple sclerosis patients. Eur J Neurol. https:\/\/doi.org\/10.1111\/ene.12119","journal-title":"Eur J Neurol"},{"key":"10237_CR29","unstructured":"NICE (2007) Natalizumab for the treatment of adults with highly active relapsing\u2013remitting multiple sclerosis. In: NICE Technol. Apprais. Guid. [TA127]. https:\/\/www.nice.org.uk\/guidance\/ta127"},{"key":"10237_CR30","doi-asserted-by":"publisher","first-page":"718","DOI":"10.1002\/ana.10551","volume":"53","author":"F Barkhof","year":"2003","unstructured":"Barkhof F, Rocca M, Francis G et al (2003) Validation of diagnostic magnetic resonance imaging criteria for multiple sclerosis and response to interferon \u03b21a. Ann Neurol 53:718\u2013724. https:\/\/doi.org\/10.1002\/ana.10551","journal-title":"Ann Neurol"},{"key":"10237_CR31","doi-asserted-by":"publisher","first-page":"14","DOI":"10.1111\/ene.12799","volume":"22","author":"P Gallo","year":"2015","unstructured":"Gallo P, Van Wijmeersch B (2015) Overview of the management of relapsing-remitting multiple sclerosis and practical recommendations. Eur J Neurol 22:14\u201321","journal-title":"Eur J Neurol"},{"key":"10237_CR32","doi-asserted-by":"publisher","first-page":"479","DOI":"10.1177\/1352458507085555","volume":"14","author":"J R\u00edo","year":"2008","unstructured":"R\u00edo J, Rovira A, Tintor\u00e9 M et al (2008) Relationship between MRI lesion activity and response to IFN-beta in relapsing-remitting multiple sclerosis patients. MultScler 14:479\u2013484. https:\/\/doi.org\/10.1177\/1352458507085555","journal-title":"MultScler"},{"key":"10237_CR33","doi-asserted-by":"publisher","first-page":"449","DOI":"10.1056\/NEJMoa1709919","volume":"378","author":"J Park","year":"2018","unstructured":"Park J, Rivere I, Gonen M et al (2018) Long-term follow-up of CD19 CAR therapy in acute lymphoblastic leukemia. N Engl J Med 378:449\u2013459. https:\/\/doi.org\/10.1056\/NEJMoa1709919","journal-title":"N Engl J Med"},{"key":"10237_CR34","doi-asserted-by":"publisher","first-page":"62","DOI":"10.1016\/j.retram.2018.03.004","volume":"66","author":"S Grupp","year":"2018","unstructured":"Grupp S (2018) Beginning the CAR T cell therapy revolution in the US and EU. Curr Res Transl Med 66:62\u201364. https:\/\/doi.org\/10.1016\/j.retram.2018.03.004","journal-title":"Curr Res Transl Med"},{"key":"10237_CR35","doi-asserted-by":"publisher","first-page":"214","DOI":"10.1016\/j.jcyt.2020.01.015","volume":"22","author":"J Cao","year":"2020","unstructured":"Cao J, Wang H, Gao W et al (2020) The incidence of cytokine release syndrome and neurotoxicity of CD19 chimeric antigen receptor\u2013T cell therapy in the patient with acute lymphoblastic leukemia and lymphoma. Cytotherapy 22:214\u2013226. https:\/\/doi.org\/10.1016\/j.jcyt.2020.01.015","journal-title":"Cytotherapy"},{"key":"10237_CR36","doi-asserted-by":"publisher","first-page":"2452","DOI":"10.1016\/j.ymthe.2017.07.013","volume":"25","author":"L Alabanza","year":"2017","unstructured":"Alabanza L, Pegues M, Geldres C et al (2017) Function of novel anti-CD19 chimeric antigen receptors with human variable regions is affected by hinge and transmembrane domains. MolTher 25:2452\u20132465. https:\/\/doi.org\/10.1016\/j.ymthe.2017.07.013","journal-title":"MolTher"},{"key":"10237_CR37","doi-asserted-by":"publisher","first-page":"270","DOI":"10.1038\/s41591-019-0737-3","volume":"26","author":"JN Brudno","year":"2020","unstructured":"Brudno JN, Lam N, Vanasse D et al (2020) Safety and feasibility of anti-CD19 CAR T cells with fully human binding domains in patients with B cell lymphoma. Nat Med 26:270\u2013280. https:\/\/doi.org\/10.1038\/s41591-019-0737-3","journal-title":"Nat Med"},{"key":"10237_CR38","unstructured":"DeAngelo D, Ghobadi A, Park J et al (2017) Clinical outcomes for the phase 2, single-arm, multicenter trial of JCAR015 in adult B-ALL (ROCKET Study). In: 32nd Annu. Meet. Pre-Conference Programs Soc. Immunother. Cancer (SITC 2017)"},{"key":"10237_CR39","doi-asserted-by":"publisher","first-page":"750","DOI":"10.1158\/2159-8290.CD-17-1368","volume":"8","author":"A Taraseviciute","year":"2018","unstructured":"Taraseviciute A, Tkachev V, Ponce R et al (2018) Chimeric antigen receptor T cell\u2014mediated neurotoxicity in nonhuman primates. Cancer Discov 8:750\u2013763. https:\/\/doi.org\/10.1158\/2159-8290.CD-17-1368","journal-title":"Cancer Discov"},{"key":"10237_CR40","doi-asserted-by":"publisher","first-page":"517","DOI":"10.1016\/S0140-6736(14)61403-3.T","volume":"385","author":"DW Lee","year":"2015","unstructured":"Lee DW, Kochenderfer JN, Stetler-Stevenson M et al (2015) T cells expressing CD19 chimeric antigen receptors for acute lymphoblastic leukaemia in children and young adults: a phase 1 dose-escalation trial. Lancet 385:517\u2013528. https:\/\/doi.org\/10.1016\/S0140-6736(14)61403-3.T","journal-title":"Lancet"},{"key":"10237_CR41","doi-asserted-by":"publisher","first-page":"739","DOI":"10.1038\/s41591-018-0036-4","volume":"24","author":"M Norelli","year":"2018","unstructured":"Norelli M, Camisa B, Barbiera G et al (2018) Monocyte-derived IL-1 and IL-6 are differentially required for cytokine-release syndrome and neurotoxicity due to CAR T cells. Nat Med 24:739\u2013748. https:\/\/doi.org\/10.1038\/s41591-018-0036-4","journal-title":"Nat Med"},{"key":"10237_CR42","doi-asserted-by":"publisher","first-page":"185","DOI":"10.1186\/1741-7015-11-185","volume":"11","author":"C Ros\u00e1rio","year":"2013","unstructured":"Ros\u00e1rio C, Zandman-Goddard G, Meyron-Holtz EG et al (2013) The Hyperferritinemic Syndrome: macrophage activation syndrome, Still\u2019s disease, septic shock and catastrophic antiphospholipid syndrome. BMC Med 11:185. https:\/\/doi.org\/10.1186\/1741-7015-11-185","journal-title":"BMC Med"},{"key":"10237_CR43","doi-asserted-by":"publisher","first-page":"877","DOI":"10.1093\/jnen\/nly064","volume":"77","author":"M Torre","year":"2018","unstructured":"Torre M, Solomon IH, Sutherland CL et al (2018) Neuropathology of a case with fatal CAR T cell-associated cerebral edema. J NeuropatholExpNeurol 77:877\u2013882. https:\/\/doi.org\/10.1093\/jnen\/nly064","journal-title":"J NeuropatholExpNeurol"},{"key":"10237_CR44","doi-asserted-by":"publisher","first-page":"297","DOI":"10.3324\/haematol.2019.229781","volume":"105","author":"I Yakoub-agha","year":"2020","unstructured":"Yakoub-agha I, Chabannon C, Bader P et al (2020) Management of adults and children undergoing chimeric antigen receptor T cell therapy: best practice recommendations of the European Society for Blood and Marrow Transplantation (EBMT) and the Joint Accreditation Committee of ISCT and EBMT (JACIE). Haematologica 105:297\u2013316. https:\/\/doi.org\/10.3324\/haematol.2019.229781","journal-title":"Haematologica"},{"key":"10237_CR45","doi-asserted-by":"publisher","first-page":"224","DOI":"10.1126\/scitranslmed.3008226","volume":"6","author":"ML Davila","year":"2014","unstructured":"Davila ML, Riviere I, Wang X et al (2014) Efficacy and toxicity management of 19\u201328z CAR T cell therapy in B cell acute lymphoblastic leukemia. Sci Transl Med 6:224\u2013225. https:\/\/doi.org\/10.1126\/scitranslmed.3008226","journal-title":"Sci Transl Med"},{"key":"10237_CR46","doi-asserted-by":"publisher","DOI":"10.1007\/s00134-020-06193-1","author":"E Azoulay","year":"2020","unstructured":"Azoulay E, Darmon M, Valade S (2020) Acute life theatening toxicity from CAR-T cell therapy. Intensive Care Med. https:\/\/doi.org\/10.1007\/s00134-020-06193-1","journal-title":"Intensive Care Med"},{"key":"10237_CR47","doi-asserted-by":"publisher","first-page":"5702","DOI":"10.1182\/blood.V128.22.5702.5702","volume":"128","author":"AL Garfall","year":"2016","unstructured":"Garfall AL, Lancaster E, Stadtmauer EA et al (2016) Posterior Reversible Encephalopathy Syndrome (PRES) after Infusion Of Anti-Bcma CAR T cells (CART-BCMA) for multiple myeloma: successful treatment with cyclophosphamide. Blood 128:5702. https:\/\/doi.org\/10.1182\/blood.V128.22.5702.5702","journal-title":"Blood"},{"key":"10237_CR48","doi-asserted-by":"publisher","DOI":"10.1007\/s12185-020-02840-x","author":"K Sdrimas","year":"2020","unstructured":"Sdrimas K, Diaz M, Jose P, Lazaros FC (2020) Progressive multifocal leukoencephalopathy after CAR T therapy. Int J Hematol. https:\/\/doi.org\/10.1007\/s12185-020-02840-x","journal-title":"Int J Hematol"},{"key":"10237_CR49","doi-asserted-by":"publisher","first-page":"121","DOI":"10.1182\/blood-2017-07-793760","volume":"131","author":"JA Hill","year":"2018","unstructured":"Hill JA, Li D, Hay KA et al (2018) Infectious complications of CD19-targeted chimeric antigen receptor\u2014modified T cell immunotherapy. Blood 131:121\u2013130. https:\/\/doi.org\/10.1182\/blood-2017-07-793760","journal-title":"Blood"}],"container-title":["Journal of Neurology"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s00415-020-10237-3.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s00415-020-10237-3\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s00415-020-10237-3.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,3,24]],"date-time":"2021-03-24T05:14:13Z","timestamp":1616562853000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s00415-020-10237-3"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,11,2]]},"references-count":49,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2021,4]]}},"alternative-id":["10237"],"URL":"https:\/\/doi.org\/10.1007\/s00415-020-10237-3","relation":{},"ISSN":["0340-5354","1432-1459"],"issn-type":[{"value":"0340-5354","type":"print"},{"value":"1432-1459","type":"electronic"}],"subject":[],"published":{"date-parts":[[2020,11,2]]},"assertion":[{"value":"7 September 2020","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"17 September 2020","order":2,"name":"revised","label":"Revised","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"18 September 2020","order":3,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"2 November 2020","order":4,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Compliance with ethical standards"}},{"value":"Dr Tallantyre has received honorarium for consulting work from Novartis, Biogen and Roche, and travel grants to attend or speak at educational meetings from Merck, Roche, Takeda and Novartis. Dr Evans received travel expenses to attend educational meetings from Janssen and BOPA, consulting fees from BOPA, and speaker fees from Jazz. Dr Parry-Jones has no conflicts of interest. Dr Morgan written a book about\u00a0intensive care medicine and been paid by the publishers. Dr Jones has received Travel grants from AbbVie. Dr Ingram has received consulting fees from Celgene and Novartis, speaker fees from Kite Gilead and Alexion, and travel sponsorship from Alexion, Jazz pharmaceuticals and Novartis.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflicts of interest"}}]}}